Reasonable two-stage adaptive designs for single-arm phase II clinical trials

Pharmaceutical Statistics
Kosuke Kashiwabara, Yutaka Matsuyama

Abstract

In cancer phase II trials, determining the sample size of a single-arm two-stage design remains a challenge. To overcome this problem, Simon's two-stage design was extended to an adaptive design: at the interim analysis, the total sample size can be set to either of the two preplanned values. However, without any restriction on design construction, an optimal or suboptimal design derived may have counter-intuitive or unreasonable design features, which make the chosen design less persuasive and inefficient. Thus, we thoroughly examined how the expected, total, and maximum sample sizes of the optimal or suboptimal designs are affected by excluding the counter-intuitive or unreasonable designs. We adopted the four optimality criteria: minimizing the expected sample size at the null hypothesis (O1), minimizing the maximum expected sample size over the hypotheses (O2), and minimizing the maximum sample sizes with additional adaption of either of the former two (O3 or O4, respectively). We found that focusing on reasonable design may drastically reduce the maximum sample size when the first optimality criterion is applied. Under the other optimality criteria, although the impact on optimality brought by our proposed strategy may be ...Continue Reading

References

May 1, 1992·Statistics in Medicine·S J Green, S Dahlberg
Mar 1, 1989·Controlled Clinical Trials·R Simon
Nov 15, 1980·British Medical Journal·D G Altman
Aug 30, 1997·Statistics in Medicine·D F Heitjan
Aug 22, 2001·Controlled Clinical Trials·S H JungK M Kim
Jul 12, 2002·Statistics in Medicine·Say-Beng Tan, David Machin
Jul 16, 2002·JAMA : the Journal of the American Medical Association·Scott D HalpernJesse A Berlin
Jul 31, 2002·Journal of Biopharmaceutical Statistics·Jonathan Shuster
Feb 3, 2004·Statistics in Medicine·Sin-Ho JungStephen L George
Jun 8, 2004·Biometrics·Yong Lin, Weichung J Shih
Feb 16, 2006·Statistics in Medicine·Anindita Banerjee, Anastasios A Tsiatis
Oct 19, 2007·Clinical Trials : Journal of the Society for Clinical Trials·Fei Ye, Yu Shyr
Apr 1, 2008·Clinical Trials : Journal of the Society for Clinical Trials·J Jack Lee, Diane D Liu
Dec 14, 2011·Biometrics·Stefan Englert, Meinhard Kieser
Mar 15, 2012·Statistics in Medicine·Gaohong DongStephen Marcella
Apr 24, 2012·Clinical Trials : Journal of the Society for Clinical Trials·Yimei LiDaniel F Heitjan
Jul 19, 2012·Statistics in Medicine·Satoshi TeramukaiSarah Zohar
Jul 23, 2013·Biometrical Journal. Biometrische Zeitschrift·Stefan Englert, Meinhard Kieser
Mar 18, 2015·Statistics in Medicine·Stefan Englert, Meinhard Kieser
Aug 20, 2015·The New England Journal of Medicine·David M HymanJosé Baselga
Nov 4, 2015·Statistics in Medicine·Guogen ShanShawn Gerstenberger
May 26, 2017·Statistical Methods in Medical Research·Seongho Kim, Weng Kee Wong

❮ Previous
Next ❯

Citations

Aug 30, 2020·Pharmaceutical Statistics·Martin LawAdrian P Mander

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.